The CMS has issued a reimbursement code to Uromedica for its ProACT Adjustable Continence Therapy for Men, a system indicated for the treatment of adult men with stress incontinence caused by post-surgical intrinsic sphincter deficiency that lasts for at least 12 months and has not responded to conservative therapy. The system has already been launched by the company in the US.
Uromedica's continence therapy system wins CMS reimbursement
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.